Product Donations
We believe that donations of medicine can play a role in meeting an immediate need for patients in low- and middle-income countries who cannot currently afford biologic medicines. We are, therefore, committed to donating our medicines through organized programs and partnerships in accordance with local regulations. Amgen is currently piloting an initiative ex-U.S. to donate medicines to humanitarian NGOs serving patients in need in low- and middle-income countries.
Case Study: Product Donations to Support Cancer Care in 18 Low-and Middle-Income Countries
In 2018 Amgen donated US $93 million of NEUPOGEN® (filgrastim), Neulasta® (pegfilgrastim) and Vectibix® (panitumumab) to Direct Relief to serve approximately 7,400 low-income patients.
Direct Relief, a long-standing Amgen partner, will ensure distribution of the medicines through a network of high-quality cancer hospitals and clinics across 18 low- and middle-income countries including African countries such as Ethiopia, Ghana, Malawi, Senegal, Tanzania and Uganda.
During 2020, Amgen donated nearly 830,000 units of medicine through Direct Relief, with a value of approximately $70 million (wholesale acquisition cost) to serve patients in 29 low- and middle-income countries – nearly double the number of countries as in 2019. We also more than doubled the number of products we donate, from three to seven.
Expanding Product Donations to More Products and More Patients
During 2020, Amgen donated nearly 830,000 units of medicine through Direct Relief, with a value of approximately $70 million (wholesale acquisition cost) to serve patients in 29 low- and middle-income countries – nearly double the number of countries versus 2019. We also more than doubled the number of products we donate, from three to seven.
